Mary Miller - 01 Apr 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Legal Officer
Signature
/s/ Adam D. Levy, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
01 Apr 2025
Net transactions value
$0
Form type
4
Filing time
03 Apr 2025, 16:32:43 UTC
Previous filing
04 Mar 2025
Next filing
18 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Award $0 +15,616 $0.000000 15,616 01 Apr 2025 Common Stock 15,616 $1.68 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option vest on April 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney